<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Biodesix Inc — News on 6ix</title>
<link>https://6ix.com/company/biodesix-inc</link>
<description>Latest news and press releases for Biodesix Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 06 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/biodesix-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68354be578dffbe2df0e549e.webp</url>
<title>Biodesix Inc</title>
<link>https://6ix.com/company/biodesix-inc</link>
</image>
<item>
<title>Biodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery & Pipeline Development</title>
<link>https://6ix.com/company/biodesix-inc/news/biodesix-announces-aacr-2026-posters-and-presentations-highlighting-novel-diagnostic-test-discovery-and-pipeline-development</link>
<guid isPermaLink="true">https://6ix.com/company/biodesix-inc/news/biodesix-announces-aacr-2026-posters-and-presentations-highlighting-novel-diagnostic-test-discovery-and-pipeline-development</guid>
<pubDate>Mon, 06 Apr 2026 04:00:00 GMT</pubDate>
<description>Includes novel proteomic and genomic approaches to oncology therapeutic selection, response monitoring, and Molecular Residual Disease (MRD) testing</description>
</item>
<item>
<title>Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis</title>
<link>https://6ix.com/company/biodesix-inc/news/biodesix-announces-the-largest-lung-nodule-biomarker-clinical-validation-study-ever-published-supporting-earlier-lung-cancer-diagnosis</link>
<guid isPermaLink="true">https://6ix.com/company/biodesix-inc/news/biodesix-announces-the-largest-lung-nodule-biomarker-clinical-validation-study-ever-published-supporting-earlier-lung-cancer-diagnosis</guid>
<pubDate>Fri, 20 Mar 2026 04:00:00 GMT</pubDate>
<description>A retrospective pooled analysis of 1,100 patients demonstrates the Nodify CDT® test’s consistent clinical performance across nodule sizes and patient</description>
</item>
<item>
<title>Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights</title>
<link>https://6ix.com/company/biodesix-inc/news/biodesix-announces-fourth-quarter-and-fiscal-year-2025-results-and-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/biodesix-inc/news/biodesix-announces-fourth-quarter-and-fiscal-year-2025-results-and-highlights</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>Delivered 41% revenue growth and 83% gross margin in Q4 2025; Improved Net Loss by 52% and achieved first-ever Adjusted EBITDA positivity in Q4 2025; FY2026</description>
</item>
<item>
<title>Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026</title>
<link>https://6ix.com/company/biodesix-inc/news/biodesix-report-fourth-quarter-full-110000301</link>
<guid isPermaLink="true">https://6ix.com/company/biodesix-inc/news/biodesix-report-fourth-quarter-full-110000301</guid>
<pubDate>Thu, 12 Feb 2026 11:00:00 GMT</pubDate>
<description>LOUISVILLE, Colo., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the fourth quarter and year ended December 31, 2025 after the close of trading on Thursday, February 26. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast</description>
</item>
<item>
<title>Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited)</title>
<link>https://6ix.com/company/biodesix-inc/news/biodesix-announces-preliminary-fourth-quarter-110000096</link>
<guid isPermaLink="true">https://6ix.com/company/biodesix-inc/news/biodesix-announces-preliminary-fourth-quarter-110000096</guid>
<pubDate>Mon, 12 Jan 2026 11:00:00 GMT</pubDate>
<description>Estimated Q4 2025 Revenue of $28.8 million, an increase of 41%; Grew full-year revenue to an estimated $88.5 million, an increase of 24%; Affirms guidance of Adjusted EBITDA positivity in Q4 2025. LOUISVILLE, Colo., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX) (the company), a leading diagnostic solutions company, today announced its preliminary financial results for the fourth quarter and year ended December 31, 2025 (fiscal 2025). The financial results included in this relea</description>
</item>
<item>
<title>Biodesix to Present New Data at Two Major Upcoming Scientific Meetings</title>
<link>https://6ix.com/company/biodesix-inc/news/biodesix-present-data-two-major-132200201</link>
<guid isPermaLink="true">https://6ix.com/company/biodesix-inc/news/biodesix-present-data-two-major-132200201</guid>
<pubDate>Wed, 03 Dec 2025 13:22:00 GMT</pubDate>
<description>Clinical utility data for Nodify Lung® tests to be presented at North American Conference on Lung Cancer (NACLC) highlighting potential for earlier diagnosis of lung cancer Development data for a new ultra-sensitive ESR1 assay for breast cancer treatment resistance monitoring to be presented at San Antonio Breast Cancer Symposium (SABCS) LOUISVILLE, Ky., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announces several poster presentation</description>
</item>
<item>
<title>Biodesix Announces Third Quarter 2025 Results and Highlights</title>
<link>https://6ix.com/company/biodesix-inc/news/biodesix-announces-third-quarter-2025-210100541</link>
<guid isPermaLink="true">https://6ix.com/company/biodesix-inc/news/biodesix-announces-third-quarter-2025-210100541</guid>
<pubDate>Mon, 03 Nov 2025 21:01:00 GMT</pubDate>
<description>Q3 2025 Revenue of $21.8 million, an increase of 20% over Q3 2024; Q3 2025 gross profit margin of 81%, a 400-basis point improvement from Q3 2024; Raised FY2025 Total Revenue Guidance to $84-86 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the third quarter ended September 30, 2025. “We delivered a strong</description>
</item>
<item>
<title>Biodesix to Share its R&D Roadmap during its Corporate Day Presentation at AMP Annual Meeting</title>
<link>https://6ix.com/company/biodesix-inc/news/biodesix-share-r-d-roadmap-101700366</link>
<guid isPermaLink="true">https://6ix.com/company/biodesix-inc/news/biodesix-share-r-d-roadmap-101700366</guid>
<pubDate>Thu, 30 Oct 2025 10:17:00 GMT</pubDate>
<description>Speaker panel will include collaborative case study presentations from strategic partners: Memorial Sloan Kettering Cancer Center, Bio-Rad Laboratories, and Thermo Fisher ScientificLOUISVILLE, Colo., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announces its Corporate and Scientific presentations, and exhibitor presence at the 2025 AMP Annual Meeting, November 12-15, in Boston, MA. BIODESIX WORKSHOP: On November 12, at 4:00 ET, Dr. Gar</description>
</item>
<item>
<title>Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital™ PCR High Complexity Assays</title>
<link>https://6ix.com/company/biodesix-inc/news/biodesix-announces-expanded-bio-rad-101700353</link>
<guid isPermaLink="true">https://6ix.com/company/biodesix-inc/news/biodesix-announces-expanded-bio-rad-101700353</guid>
<pubDate>Wed, 22 Oct 2025 10:17:00 GMT</pubDate>
<description>Biodesix will perform the clinical validation of ddPLEX ESR1 Mutation Detection Assay for advanced breast cancer testingLOUISVILLE, Colo., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (NYSE: BDSX), a leading diagnostics solutions company, today announced the signing of an expanded partnership agreement under which Biodesix will conduct the development, clinical validation, and regulatory submissions of in vitro diagnostic (IVD) assays to enable highly sensitive detection of multiple genomic</description>
</item>
<item>
<title>Biodesix Announces Presentations and Events at the CHEST 2025 Annual Meeting</title>
<link>https://6ix.com/company/biodesix-inc/news/biodesix-announces-presentations-events-chest-100900407</link>
<guid isPermaLink="true">https://6ix.com/company/biodesix-inc/news/biodesix-announces-presentations-events-chest-100900407</guid>
<pubDate>Wed, 15 Oct 2025 10:09:00 GMT</pubDate>
<description>One year after launch of real-world CLARIFY study, preliminary data from the first 1,000 enrolled patients will be presentedLOUISVILLE, Colo., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announces educational events, abstracts, and activities at the 2025 CHEST Annual Meeting, October 19-22, in Chicago, Illinois. Biodesix will be presenting data from an interim analysis of the CLARIFY study in a sponsored Learning Theater presentation.</description>
</item>
<item>
<title>Biodesix Unveils October Lung Health Events in Colorado with the Association of Pulmonary Advanced Practice Providers (APAPP), American Lung Association in Colorado, and GO2 for Lung Cancer Centers of Excellence Summit</title>
<link>https://6ix.com/company/biodesix-inc/news/biodesix-unveils-october-lung-health-141300002</link>
<guid isPermaLink="true">https://6ix.com/company/biodesix-inc/news/biodesix-unveils-october-lung-health-141300002</guid>
<pubDate>Mon, 06 Oct 2025 14:13:00 GMT</pubDate>
<description>Biodesix partners with three leading Lung Health organizations to bring education and advocacy to healthcare professionals and patients LOUISVILLE, Colo., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announced three Colorado-based events in October for healthcare professionals and community members to collaborate, learn, and advocate for lung health. First Event: October 9th APAPP Know Your Nodules Event at Biodesix Head Office in Loui</description>
</item>
<item>
<title>Biodesix Announces One-for-Twenty Reverse Stock Split</title>
<link>https://6ix.com/company/biodesix-inc/news/biodesix-announces-one-twenty-reverse-120000050</link>
<guid isPermaLink="true">https://6ix.com/company/biodesix-inc/news/biodesix-announces-one-twenty-reverse-120000050</guid>
<pubDate>Thu, 11 Sep 2025 12:00:00 GMT</pubDate>
<description>LOUISVILLE, Colo., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix” or the “Company”), a leader in personalized diagnostics, today announced a one-for-twenty reverse stock split (the “Reverse Stock Split”) of the Company’s common stock, par value $0.001, which will become effective at 12:01 a.m. Eastern Time on Monday, September 15, 2025. The Company’s common stock will continue to trade under Biodesix’s existing trading symbol, BDSX, on the Nasdaq Global Market (“Nas</description>
</item>
<item>
<title>Biodesix to Participate in Lake Street Capital Markets’ 9th Annual Best Ideas Growth (BIG9) Conference</title>
<link>https://6ix.com/company/biodesix-inc/news/biodesix-participate-lake-street-capital-100000074</link>
<guid isPermaLink="true">https://6ix.com/company/biodesix-inc/news/biodesix-participate-lake-street-capital-100000074</guid>
<pubDate>Fri, 05 Sep 2025 10:00:00 GMT</pubDate>
<description>LOUISVILLE, Colo., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Robin Cowie, Chief Financial Officer, will host in-person 1x1 investor meetings at Lake Street Capital Markets’ 9th Annual Best Ideas Growth (BIG9) Conference on Thursday, September 11, 2025. Lake Street Capital Markets’ 9th Annual Best Ideas Growth (BIG9) Conference Date: Thursday, September 11, 2025Location: New York, NY1x1 meetings only About Biodesix Bi</description>
</item>
<item>
<title>Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS Diagnostics</title>
<link>https://6ix.com/company/biodesix-inc/news/biodesix-recognized-thermo-fisher-scientific-134700587</link>
<guid isPermaLink="true">https://6ix.com/company/biodesix-inc/news/biodesix-recognized-thermo-fisher-scientific-134700587</guid>
<pubDate>Tue, 19 Aug 2025 13:47:00 GMT</pubDate>
<description>Biodesix recently validated Thermo Fisher’s tissue-based Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated SequencerLOUISVILLE, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leader in personalized diagnostics, announced that the company is designated as a Thermo Fisher Scientific Center of Excellence (COE) as part of Thermo Fisher’s collaborative initiative to advance NGS-based diagnostics. The services provided to Thermo Fisher are an example of</description>
</item>
<item>
<title>Biodesix Announces Second Quarter 2025 Results and Highlights</title>
<link>https://6ix.com/company/biodesix-inc/news/biodesix-announces-second-quarter-2025-200600427</link>
<guid isPermaLink="true">https://6ix.com/company/biodesix-inc/news/biodesix-announces-second-quarter-2025-200600427</guid>
<pubDate>Thu, 07 Aug 2025 20:06:00 GMT</pubDate>
<description>Q2 2025 Revenue of $20.0 million, an increase of 12% over Q2 2024; Q2 2025 gross profit margin of 80%, a 150-basis point improvement from Q2 2024; Reiterating FY2025 Total Revenue Guidance of $80-85 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the second quarter ended June 30, 2025. “We had strong second</description>
</item>
<item>
<title>Biodesix to Present at the Canaccord Genuity 45th Annual Growth Conference</title>
<link>https://6ix.com/company/biodesix-inc/news/biodesix-present-canaccord-genuity-45th-100000483</link>
<guid isPermaLink="true">https://6ix.com/company/biodesix-inc/news/biodesix-present-canaccord-genuity-45th-100000483</guid>
<pubDate>Tue, 05 Aug 2025 10:00:00 GMT</pubDate>
<description>BOULDER, Colo., Aug. 05, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will present in a fireside chat and host in-person 1x1 investor meetings at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025. Canaccord Genuity 45th Annual Growth Conference Fireside Chat Date: Tuesday, August 12, 2025Fireside Chat Time: 4:30 PM ETLocation: Bo</description>
</item>
<item>
<title>Biodesix to Report Second Quarter 2025 Financial Results on August 7, 2025</title>
<link>https://6ix.com/company/biodesix-inc/news/biodesix-report-second-quarter-2025-100000636</link>
<guid isPermaLink="true">https://6ix.com/company/biodesix-inc/news/biodesix-report-second-quarter-2025-100000636</guid>
<pubDate>Thu, 24 Jul 2025 10:00:00 GMT</pubDate>
<description>LOUISVILLE, Colo., July 24, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the second quarter ended June 30, 2025 after the close of trading on Thursday, August 7. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this link.</description>
</item>
<item>
<title>Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation’s First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs</title>
<link>https://6ix.com/company/biodesix-inc/news/biodesix-partners-association-pulmonary-advanced-101700660</link>
<guid isPermaLink="true">https://6ix.com/company/biodesix-inc/news/biodesix-partners-association-pulmonary-advanced-101700660</guid>
<pubDate>Tue, 10 Jun 2025 10:17:00 GMT</pubDate>
<description>Nation’s first CME-accredited course for APPs on clinical application of diagnostic biomarkers in Lung Nodule and Lung Cancer patient programsLOUISVILLE, Colo., June 10, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that it is partnering with the Association of Pulmonary Advanced Practice Providers (APAPP) to bring new educational programs aimed at their professional membership to better provide access and timely care to patients</description>
</item>
<item>
<title>Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting</title>
<link>https://6ix.com/company/biodesix-inc/news/biodesix-announces-data-veristrat-test-210300703</link>
<guid isPermaLink="true">https://6ix.com/company/biodesix-inc/news/biodesix-announces-data-veristrat-test-210300703</guid>
<pubDate>Thu, 22 May 2025 21:03:00 GMT</pubDate>
<description>New data from the INSIGHT study demonstrates the VeriStrat Host Immune Classifier (HIC)’s ability to predict overall survival in patients with non-small cell lung cancer treated with immunotherapyLOUISVILLE, Colo., May 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that new data will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois at 2:30 pm ET on Saturday, May 31st. The</description>
</item>
<item>
<title>Biodesix to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/biodesix-inc/news/biodesix-participate-upcoming-investor-conferences-100000214</link>
<guid isPermaLink="true">https://6ix.com/company/biodesix-inc/news/biodesix-participate-upcoming-investor-conferences-100000214</guid>
<pubDate>Wed, 21 May 2025 10:00:00 GMT</pubDate>
<description>LOUISVILLE, Colo., May 21, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that members of the Biodesix management team, will participate in two upcoming investor conferences: 22nd Annual Craig-Hallum Institutional Investor Conference 1x1 MeetingsDate: Wednesday, May 28, 2025 Location: Minneapolis, MN 45th Annual William Blair Growth Stock Conference Presentation and 1x1 Meetings Date and Time: Wednesday, June 4, 2025 at 9:20 AM CTL</description>
</item>
</channel>
</rss>